Market Cap N/A
Revenue (ttm) 46.74M
Net Income (ttm) -114.33M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 2,000
Avg Vol 13,580
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 78%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Phone: 650 516 4310
Address:
960 San Antonio Road, Palo Alto, United States
Latest News on SCLXW